We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling.
Our proprietary platform
Using proven and patented protocols, we can obtain, preserve and utilise human extracellular matrix (ECM) from healthy and diseased tissues to generate cellular models with bioactive scaffolds.
The flexible platform, which is based on extensive research and validation, is applicable to multiple organs, indications and fields.
We have reliable access to human tissues including our own biobank, as well as strong network links to hospitals, biobanks and KOLs worldwide.
Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers.
For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.